Register to gain access to personalised information regarding Brand, the indications your are treating regularly, dosing guidelines and resources such as Major Studies, Patient Information and short videos curated to your special interest.

Prevention of Atherothrombotic Events in Chronic Peripheral Artery Disease

Xarelto is indicated for the prevention of atherothrombotic events in adults with symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.1

Protection starts with getting to know your patient

How do you protect your patients like Roberto?

What does the future look like for your patients with PAD?

Are you aware of the risks that patients with PAD face?

Improve the outcomes that matter for patients like Roberto

What does long-term protection look like to you?

*RRR was calculated as 1-HR.

See how the benefit increases over time5

Bleeding was generally manageable with no significant increase in the most serious types vs aspirin alone6

Independent retrospective cohort analysis US database

*Proportion of patients experiencing bleeding events were calculated as percentages from the number of events and the number of patients in each treatment group.

^†Primary safety endpoint. Based on a modified version of the ISTH bleeding criteria7 with a broader definition for major bleeding events defined as fatal bleeding, symptomatic bleeding into a critical organ or area (e.g. intracranial), surgical site bleeding requiring reoperation or bleeding events requiring hospital admission with or without an overnight stay. Reported sites of major bleeding included gastrointestinal, intracranial, skin or injection site, and urinary.

^‡If a participant had more than one event of major bleeding, only the most serious bleeding event was counted in these analyses.

^§Non-fatal, symptomatic.

Who to protect… for what matters most

Protect your patients at high risk

Meet Mary

Symptomatic PAD and diabetes

Because of her diabetes, Mary is at greater risk of ischaemic events and limb events.8,9

She has multiple comorbidities and existing treatments.

Click on ‘TREAT MARY’ to see how you could help protect patients like her.

Characteristics

60 years old
164 cm
85 kg

Medical history

Symptomatic PAD since Nov 2018
Intermediate claudification on left calf already on gentle slopes
T2DM (diagnosed 1986)
Media sclerosis on both sides
Obesity grade I
Dyslipidaemia
Arterial hypertension
Father has apoplexy and diabetes

Treatment

Aspirin 100 mg 1x1
Metformin 850 mg 3x1
Levemir s.c. in the evening
Lercanidipine 10 mg 2x1
Moxonidine 0.3 mg 1x1
Valsartan Comp 160/25-0-Valsartan 160
Simvastatin 40 mg 1x1
Omeprazole 50 mg 2x1
Metoprolol 100 mg 1x1

Treat Mary

Symptomatic PAD and diabetes

Because of her diabetes, Mary is at greater risk of ischaemic events and limb events.8,9

She has multiple comorbidities and existing treatments.

Efficacy

Protect patients like Mary

Could you do more to protect Mary? In patients with symptomatic PAD and diabetes, treatment with Xarelto^® vascular dose plus aspirin led to a

* RRR was calculated as 1-HR.

^† Including major amputations.

Meet Henry

Chronic PAD and CAD

Patients with both PAD and CAD are at a higher risk of ischaemic events.10,12

Henry is already on multiple treatments and has several comorbidities.

Click on ‘TREAT HENRY’ to see how you could help protect patients like him.

Characteristics

71 years old
175 cm
78 kg

Medical history

Double coronary artery disease
CAD intervention
PAD (PTA) and stenting for superficial femoral artery lesions
Arterial hypertension

Treatment

Aspirin 100 mg (1-0-0)
Simvastatin 40 mg (0-0-1)
Amlodipine 5 mg (1-0-0)
Ramipril 5 mg (1-0-0)

Treat Henry

Chronic PAD and CAD

Patients with both PAD and CAD are at a higher risk of ischaemic events.10,12

Henry is already on multiple treatments and has several comorbidities.

Efficacy

Protect patients like Henry

Could you do more to protect Henry? In patients with CAD and PAD, treatment with Xarelto^® vascular dose plus aspirin led to a

* RRR was calculated as 1-HR.

Additional risk-benefit considerations before prescribing Xarelto

Protection requires your clinical expertise

* Please see the SmPC/Full Prescribing information for more information

Protect your patients like Roberto

Prescribe Xarelto vascular dose plus aspirin to help improve the outcomes that matter

BID, twice daily; CAD, coronary arterial disease; CI, confidence interval; CrCl, creatinine clearance; CV, cardiovascular; DAPT; dual antiplatelet therapy; HR, hazard rain; ICH, intracranial haemorrhage; MACE, major adverse cardiovascular event; MALE, major adverse limb event; NSAID, non-steroidal anti-inflammatory; PAD, peripheral arterial disease; RRR, relative risk reduction, T2DM, type II diabetes mellitus.

PP-XAR-ALL-2121-1

References

Bayer AG. Xarelto^® (rivaroxaban) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf. Bayer AG. Xarelto^® (rivaroxaban) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_en.pdf. Return to content
Swaminathan A et al. Vascular Health Risk Management 2014;10:417–424. Return to content
Diehm C, et al. Circulation 2009;120:2053–2061. Return to content
Anand SS, et al. Lancet 2018;391:219–229. Return to content
Eikelboom JW, et al. J Am Coll Cardiol 2019:74:1519–1528. Return to content
Eikelboom JW, et al. N Engl J Med 2017;377:1319–1330. Return to content
Schulman S, et al. J Thromb Haemost 2005;3:692–694. Return to content
Cavender MA, et al. Circulation 2015;132:923–931. Return to content
Nativel M, et al. Cardiovasc Diabetol 2018;17(1):138. Return to content
Steg PG, et al. JAMA 2007;297:1197–1206 Return to content
Knuuti, et al. Eur Heart J 2020:41:407–477. Return to content
Connolly SJ, et al. Lancet 2018:391:205–218. Return to content
Aspirin Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4172/smpc. Aspirin Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/4172/smpc. Return to content

RELATED PODCAST
CAD or symptomatic PAD discussion

RELATED VIDEOS
Coronary Artery Disease Causes and Consequences

DOSING GUIDE

PRACTICAL MANAGEMENT

PRESCRIBING INFORMATION

Prevention of Atherothrombotic Events in Chronic Peripheral Artery Disease

Protection starts with getting to know your patient

What does the future look like for your patients with PAD?